Brand · Extended-release tablet
Hysingla 100 mg extended-release tablet price what pharmacies pay, and what you should
There is no weekly pharmacy acquisition cost for hysingla 100 mg extended-release tablet this week. The makers, package codes, recalls and label are below.
What people paid for hysingla 100 mg extended-release tablet
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Recalls
Showing the 6 most relevant of 16 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
Every manufacturer and package code
1 company sell hysingla 100 mg extended-release tablet under 1 package code (NDC).
| Maker | Package codes | Per unit |
|---|---|---|
| Knoa Pharma LLC | 59011-276-60 | - |
All 1 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Other hysingla strengths and forms
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 20 mg extended-release tablet Brand | $13.31 | $399.18 / 30 tablets |
| 30 mg extended-release tablet Brand | $19.40 | $581.86 / 30 tablets |
| 40 mg extended-release tablet Brand | $26.12 | $783.73 / 30 tablets |
| 60 mg extended-release tablet Brand | $36.13 | $1,083.88 / 30 tablets |
| 80 mg extended-release tablet Brand | $48.66 | $1,459.65 / 30 tablets |
Official label & what changed
These highlights do not include all the information needed to use HYSINGLA® ER safely and effectively. See full prescribing information for HYSINGLA ER. HYSINGLA® ER (hydrocodone bitartrate) extended-release tablets, for oral use, CII Initial U.S. Approval: 1943
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYSINGLA ER
Addiction, Abuse, and Misuse
Because the use of HYSINGLA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1)].
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of HYSINGLA ER, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of HYSINGLA ER are essential. Instruct patients to swallow HYSINGLA ER tablets whole; crushing, chewing, or dissolving HYSINGLA ER tablets can cause rapid release and absorption of a potentially fatal dose of hydrocodone [see Warnings and Precautions (5.2)].
Accidental Ingestion
Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can result in a fatal overdose of hydrocodone [see Warnings and Precautions (5.2)].
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of HYSINGLA ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3), Drug Interactions (7)].
Neonatal Opioid Withdrawal Syndrome (NOWS)
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.4)].
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.5)].
Cytochrome P450 3A4 Interaction
The concomitant use of HYSINGLA ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Regularly evaluate patients receiving HYSINGLA ER and any CYP3A4 inhibitor or inducer [see Warnings and Precautions (5.6), Drug Interactions (7), and Clinical Pharmacology (12.3)].
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYSINGLA ER
See full prescribing information for complete boxed warning.
HYSINGLA ER exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing, and reassess regularly for these behaviors and conditions. (5.1)
Serious, life-threatening, or fatal respiratory depression may occur, especially upon initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of HYSINGLA ER are essential. Instruct patients to swallow HYSINGLA ER whole to avoid exposure to a potentially fatal dose of hydrocodone. (5.2)
Accidental ingestion of HYSINGLA ER, especially by children, can result in fatal overdose of hydrocodone. (5.2)
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.3, 7)
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery (5.4)
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (5.5)
Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone. (5.6, 7, 12.3)
Recent major changes (as listed on the label)
Boxed Warning | 12/2025 |
Indications and Usage (1) | 12/2025 |
Dosage and Administration (2.2, 2.3, 2.7) | 12/2025 |
Warnings and Precautions (5.1, 5.2, 5.3, 5.14, 5.16) | 12/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about hysingla 100 mg extended-release tablet
Who makes hysingla 100 mg extended-release tablet?
1 company: Knoa Pharma LLC. See every package code.
Is hysingla in shortage?
No shortage is reported right now. We check every day.
Has hysingla been recalled?
16 recalls on record. Recalls name specific lots - check yours.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about hysingla 100 mg extended-release tablet
No comments yet. Questions, tips, what worked for you - start the conversation.